3M New Zealand

SearchContact us

About 3M

 

 

3M Innovation



To cut or not to cut

 

 

 

 

 

 

 

Aldara is the first in a new class of drugs - immune response modifiers (IRMs) - that demonstrate both anti-viral and anti-tumour activity.

More Innovation stories

 

 

The foreskin debate has raged for decades. Claims and counter-claims over hygiene, medical conditions, sexual performance and the invasive nature of the procedure have featured in the circumcision debate.

In reality, circumcision seems to have few valid medical reasons. Common reasons for circumcision are religious or cultural but in New Zealand these considerations don't dominate our national psyche.

The main reason in many countries seems to have been because "everyone else has done it" and in this regard we appear to be aligned with the United Kingdom and Australia in the swing against circumcision over recent decades.

Now there is another compelling reason to remain intact. New evidence in the treatment of genital warts has shown that 3M's cream Aldara has particularly high success rates in uncircumcised males.

Genital warts are caused by the human papillomavirus (HPV) and given that it is the most common sexually transmitted infection in New Zealand today, the cream's success with the uncircumcised is good news for many that suffer from this unsightly and infectious condition.

The recent research, published in the International Journal of STD and AIDS1 shows that total clearance of the warts was achieved in 62% of uncircumcised males who applied 3M brand Aldara cream, three times per week.

Not only did the study show the effectiveness of Aldara in uncircumcised men, the cream is an important advance as it avoids the problems often associated with other treatments, including the rate of warts returning afterwards. Patients who clear their warts after treatment with Aldara tend to remain clear of the condition.

The research was undertaken in France and Germany to evaluate Aldara in uncircumcised men, as circumcision is not common in Europe. Previous clinical studies were conducted primarily in the US and Canada, where the large majority of men (more than 70%) are circumcised. While this is down from the rates of near 90% in the 1950s, circumcision rates in the US are still high, with 1.2million male babies thought to be circumcised every year.

In the 1950s circumcision was also big in the United Kingdom and Australasia. In Australia the rate of circumcision has decreased significantly over the past 20 years to around 15% but in Britain the rate of infant circumcision is now less than 0.5%.
The author of the Aldara study, Professor Herald Gollnick of the University of Magdeburg, Germany says the results are particularly significant for areas of the world where male circumcision is not widely performed, such as Europe and Australasia.

The increasing incidence of genital warts is a global concern, with the greatest prevalence in young adults.
"Effective treatment of the disease is of great importance not only from a medical perspective but also from a psychological and economic perspective," says Professor Gollnick.

Aldara is the first in a new class of drugs - immune response modifiers (IRMs) - that demonstrate both anti-viral and anti-tumour activity. IRMs act by stimulating the patient's own immune system to fight the virus and eliminating the warts.

A surprising fact about foreskins: The average foreskin can stretch to an area of 60 to 90 square centimetres and has more than 70 meters of nerves and 10,000 to 20,000 nerve endings.

 

 



3M New Zealand

About 3M

Visit our other sites around the world


Copyright 3M 1999 | Legal information | Privacy policy